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We read with great interest the recent article by Dr. Garattini
and Dr. Bertelè [1]. We would just like to comment on the
authors’ statement that ‘‘Quality of life, morbidity and mortality
should always be the primary hard end-points for evaluating
new drugs”. We believe that this rule should be applied with cau-
tion in the ﬁeld of chronic viral hepatitis because of the slow pro-
gression of this disease and the availability of surrogate
virological end-points. For example, we know that the quality
of life and survival of chronic hepatitis B patients can be
improved if HBV replication is suppressed in a sustained manner
[2]. Also in HCV-related chronic liver disease, a sustained virolog-
ical response, namely HCV clearance 6 months after treatment
withdrawal, is associated with increased survival and a low rate
of progression towards decompensation or hepatocellular carci-
noma [3–6]. A trial, comparing the effects of different drugs in
the setting of HBV-related or HCV-related chronic hepatitis with
survival as end-point, would be considered poorly ethical. Indeed,
it would take several decades to demonstrate the superiority of
one drug over another, and patients would be deprived of the
best treatment strategy for a prolonged period. Obviously, toxic-
ity and adverse events must be carefully monitored in trials with
a surrogate endpoint. Therefore, we agree with Dr. Garattini and
Dr. Bertelè that ‘‘in some cases an endpoint that closely correlates
with a hard end-point can be used as a surrogate” and suggest
that this is the case of treatment of chronic viral hepatitis.
The authors also advocate the use of superiority rather than
non-inferiority-designed randomized controlled trials. On the
whole, we share this view, but again a caveat applies in the set-
ting of therapy with nucleoside/nucleotide analogues of hepatitis
B. In fact, it is well known that prolonged administration of ana-
logues is associated with the emergence of resistant mutations.
Resistant variants cause viral rebound and the loss of histological
and clinical beneﬁts associated with viral suppression [7]. Ana-
logues entecavir and tenofovir have high antiviral power (77–
94% undetectability after 2 years of therapy) and a low rate of
mutation emergence. To date, the rate of resistance to entecavir
has been as low as 1.2% at 6 years and null for tenofovir at
3 years. However, what will happen in patients treated for 20
or 30 years? Resistance to analogues will probably increase in
the long term. Consequently, new drugs with similar antiviral
powers and resistance rates as entecavir and tenofovir, but with
different resistance proﬁles might be useful weapons in the ﬁght
against HBV. Such drugs may be effective in patients whoJournal of Hepatology 2responded poorly to previous compounds. Moreover, the avail-
ability of multiple non-inferior drugs would give the physician
a better opportunity to ‘‘customize” treatment for individual
patients. Lastly, new non-inferior drugs with lower costs than
previous drugs would be welcome.
In non-inferior trials, it is important that the margin of non-
inferiority is based on clinical grounds. In fact, using a wide mar-
gin of non-inferiority, a clearly inferior treatment would be con-
sidered non-inferior. In other words, a wide non-inferiority
margin does not allow us to translate into the clinical setting
what is ‘‘non-inferior” from a statistical point of view.
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